The cardiac ryanodine receptor (RyR2) is the sarcoplasmic reticulum (SR) Ca 2þ release channel which is responsible for generation of the cytosolic Ca 2þ transient required for activation of cardiac contraction. RyR2 functional activity is governed by changes in [Ca 2þ ] on both the cytosolic and luminal phase of the RyR2 channel. Activation of RyR2 by cytosolic Ca 2þ results in Ca 2þ -induced Ca 2þ release (CICR) from the SR. The decline in luminal [Ca 2þ ] following release contributes to termination of CICR and Ca 2þ signalling refractoriness through the process of luminal Ca 2þ -dependent deactivation of RyR2s. The control of RyR2s by luminal Ca 2þ involves coordinated interaction of the channel with several SR proteins, including the Ca 2þ -binding protein calsequestrin (CASQ2), and the integral proteins triadin 1 (TRD) and junctin (JCN). CASQ2 in addition to serving as a Ca 2þ storage site and a luminal Ca 2þ buffer modulates RyR2 function more directly as a putative luminal Ca 2þ sensor. TRD and JCN, stimulatory by themselves, mediate the interactions between CASQ2 and RyR2. Acquired and genetic defects in proteins of this junctional Ca 2þ signalling complex lead to disease states such as cardiac arrhythmia and heart failure by impairing luminal Ca 2þ regulation of RyR2.
Introduction
Sarcoplasmic reticulum (SR) is a major Ca 2þ storage reservoir in muscle. Following electrical excitation of cardiac myocytes, Ca 2þ ions are rapidly released from the SR into the cytosol via Ca 2þ release channels known as ryanodine receptors (RyRs, of three isoforms, isoform RyR2 is preferentially expressed in the heart). Subsequently, Ca 2þ is resequestred into the SR by ATP-consuming Ca 2þ pumps (SR Ca 2þ -ATPase, SERCA). The resulting transitory elevation of cytosolic [Ca 2þ ] ([Ca 2þ ] i ), the Ca 2þ transient, is responsible for activation of contractile filaments and hence for the generation of the heart beat. Until recently, the interest in SR Ca 2þ stores has primarily focused on events occurring on their external surfaces, including, perhaps most importantly, activation of RyR2s by cytosolic Ca 2þ , a process known as Ca 2þ -induced Ca 2þ release (CICR). 1 However, more recently evidence has come to light indicating that Ca 2þ accumulated inside the SR plays a pivotal role in governing SR-mediated Ca 2þ signalling in cardiac muscle. In particular, luminal Ca 2þ -dependent changes in RyR2 gating are involved in Ca 2þ release termination and release refractoriness, processes essential for normal rhythmic activity of the heart. [2] [3] [4] [5] Ca 2þ in the SR lumen does not act alone but instead interacts with elaborate molecular machinery that senses and translates changes in luminal Ca 2þ to RyR2. The SR luminal proteins cardiac calsequestrin (CASQ2), junctin (JCN), and triadin 1 (TRD) are established parts of this complex. 6, 7 Given the importance of this molecular complex in controlling SR Ca 2þ release, it is not surprising that the acquired and genetic defects in its components lead to pathological states including cardiac arrhythmia and heart failure (HF). In this review, we intend to summarize the evidence accumulated in the literature regarding the molecular events and players involved in modulation of SR Ca 2þ release by luminal Ca 2þ and discuss the mechanisms whereby alterations in luminal Ca 2þ signalling can lead to cardiac disease.
Ca 21 in the sarcoplasmic reticulum
The total amount of Ca 2þ in the SR is determined by Ca 2þ uptake (via SERCA), Ca 2þ efflux via RyR2s, and by the binding capacity of intra-SR Ca 2þ binding sites. Most of Ca 2þ in the SR (50-90%) 8 is bound to low-affinity luminal Ca 2þ buffering protein CASQ2. The presence of bound Ca 2þ in the SR lumen allows this organelle to supply sufficient Ca 2þ for activation of the contractile machinery despite its minuscule luminal space (3.5% of cell volume, Bers, 8 [14] [15] [16] (reviewed by Gyorke et al. 13 ). These studies showed that elevation of Ca 2þ on the luminal (trans) side of the channel in the micromolar to millimolar range increases RyR2 open probability ( Figure 1A and B). 
Modulation of ryanodine receptor by sarcoplasmic reticulum luminal proteins
The Ca 2þ release channel is a macromolecular complex composed of more than a dozen of proteins centred around the RyR2. 6, 7, 23, 24 Although the bulk of the RyR2 homotetramer is situated on the cytosolic side of the SR membrane (seen on EM micrograph as the foot), a significant portion of the protein extends to the SR lumen. On the luminal side, the RyR2 is complexed with a number of proteins, including TRD, JCN, and CASQ2. (Figure 2 ). Together these proteins form the core of the Ca 2þ release channel complex and compose a network of interacting proteins at the luminal face of the junctional SR ( j SR). 6 Based on RyR2 hydropathy plots, a minimum of four putative transmembrane segments (TM1-TM4) per monomer are predicted to span the SR membrane, such that residues connecting TM1 and TM2 form the first intraluminal loop and residues TM3 and TM4 contribute to the second intraluminal loop. The second RyR2 loop is highly conserved and is enriched in charged amino acids. 25 In addition to being involved in ion conduction and -dependent interactions of CASQ2 with the RyR2 complex and itself. M1-M4 are the putative four transmembrane domains of RyR2. At low luminal Ca 2þ CASQ2 is present as a monomer (M) and it is bound to triadin and junctin; As Ca 2þ is increased above 3 mM, dimers are formed through front-to-front interactions between monomers; tetramerization (T) and polymerization (P) occur through back-to-back interactions at Ca 2þ concentrations above 3 and 5 mM, respectively. CASQ2 dissociates from triadin (and junctin) at Ca 2þ concentrations above 5-10 mM. Adapted from Wang et al. 32 selectivity, this region is also presumed to be a site of interaction with the luminal domains of TRD and JCN. 6, 26 TRD and JCN interact with each other and with the RyR2 and at the same time link CASQ2 to the RyR2 channel complex. 31 It was concluded that rather than relying on the presence of multiple discrete Ca 2þ binding sites, Ca 2þ binding to CASQ involves electrostatic attraction to negatively charged residues of CASQ. Wang et al. 32 took advantage of the ability of CASQ1 to form rectangular crystals at high ionic strengths to derive the crystal structure of the protein. These studies provided further clues as to the mechanisms of Ca 2þ binding by CASQ. Unexpectedly, in contrast to sequence analysis that provided no indication of structural repeats, the structure analysis revealed that this protein is made up of three nearly identical tandem domains, I, II, and III, each with a topology similar to that of bacterial thioredoxin. Individual monomers stack in the crystal lattice into ribbon-like polymers. In the crystal, two topologically distinct dimerization contacts have been observed: front-to-front and back-to-back. Both of these dimerization interfaces carry large numbers of acidic residues. Ca 2þ binding occurs through largely filling the electronegative pockets formed in the dimerization contacts and absorption to the negatively charged surface of the protein.
Calsequestrin

Polymerization
Park et al. 33 used a series of truncation mutants to determine the role of Ca 2þ -dependent formation of front-to-front and back-to-back contacts in CASQ2 polymerization. Conformation and polymerization states were determined in vitro by intrinsic fluorescence, circular dichroism, and Ca 2þ binding. The following model of calsequestrin folding and polymerization has been proposed based on these results (Figure 2) . In the absence of Ca 2þ , CASQ is largely unfolded due to charge repulsion. As [Ca 2þ ] is increased, CASQ thioredoxin domains are formed and come together as the charge repulsion is shielded. As Ca 2þ concentration is further increased, the front-to-front interaction occurs first because the N-terminal region involved in this contact has relatively few acidic residues. The back-to-back interaction occurs last because more Ca 2þ ions are required to shield the negatively charged amino acids in regions involved in formation of this contact, such as the Asp/Glu rich C-terminal tail. A linear polymer is eventually formed as the front-to-front and back-to-back dimers assemble at [Ca 2þ ].5 mM. At the Ca 2þ and protein concentrations within the SR, CASQ is expected to be present as a mixture of monomers, dimers, and various size multimers. Indeed electron microscopy reveals the presence of electron dense fibrous matrices in the SR of skeletal and cardiac muscle, which are made by CASQ polymers and multimers. 34 Additionally, chemical cross-linking studies showed that most of the CASQ in the SR exists in a wide range of high-molecular-mass clusters. 35 An important question that remains to be resolved is whether changes in CASQ polymerization status can occur dynamically or whether CASQ remains polymerized during a release-uptake cycle. Dynamic Ca 2þ -dependent interconversions between monomeric and polymeric forms of CASQ2 could provide an attractive mechanism for facilitated dissociation of Ca 2þ from CASQ2 in the SR during excitation-contraction coupling.
Physical association with other junctional proteins
Besides interacting with itself to form oligomers, Ca 2þ -binding protein calsequestrin interacts with other components of the junctional complex, including TRD, JCN 6, 36 ( Figure 2) , and possibly RyR2. 37 Based on protein sequence and structure analysis as well as on in vitro binding experiments, skeletal and cardiac CASQ have been suggested to interact with the putative anchoring proteins TRD and JCN through domains of charged amino acids either in its N-terminal or C-terminal regions. 6, 26, 32 Consistent with the involvement of the N-terminal region of CASQ2 in binding to the RyR2-TRD complex, a naturally occurring mutation in its N-terminus (R33Q) has been shown to disrupt functional interactions of CASQ2 with the RyR2 channel. 38 However, another mutation (D307H) that is harboured in the third thioredoxin domain of CASQ2 has been also shown to reduce CASQ2 binding to TRD. 39 These results suggest either that the CASQ2 mutations affect CASQ2 binding to TRD indirectly by altering the conformational state of the protein or that the TRD binding site is formed by several separate domains in the linear sequence of the protein. ] dynamics near the luminal side of the RyR2 channel. While clearly supporting the Ca 2þ buffering role of CASQ2, these studies are not inconsistent with direct modulatory effects of CASQ2 on RyR2 channel function. Since CASQ2 has been shown to inhibit RyR2s, 43 one would expect, for example, that knockdown of CASQ2 expression would enhance Ca 2þ spark occurrence, which was not observed. A possible explanation for this apparent discrepancy is that CASQ2 is expressed at very high level so that even after its suppression to 30% of control, a sufficient number of copies of the proteins remain to fulfil its role as a RyR2 modulator, even though its buffering capacity is reduced. Consistent with this explanation, expression of certain CASQ2 mutants (e.g. R33Q) alters SR Ca signalling in a dominant-negative manner by displacing WTCASQ2 from the RyR2 complex. 38 
Calsequestrin function
Effects of calsequestrin on ryanodine receptor channel in lipid bilayers
The direct functional effects of CASQ2 on the RyR2 channel have been studied using an in vitro reconstitution approach, i.e. lipid bilayers. 43 In these studies, CASQ2 has been found to inhibit RyR2s complexed with TRD and JCN but had no effect on purified RyR2s stripped of TRD and JCN. The inhibition was luminal Ca 2þ -dependent such that it occurred at low (20 mM) but not at high luminal Ca 2þ (2 mM). The luminal Ca 2þ dependency of the modulatory effects of CASQ2 raises the possibility that CASQ2 may serve as a luminal Ca 2þ sensor for RyR2. In support of this possibility, RyR2s lost their ability to respond to luminal Ca 2þ following purification. Moreover, purified RyR2s regained their responsiveness to luminal Ca 2þ following re-association with all three proteins (TRD, JCN, and CASQ2) but not with TRD and JCN only. Qualitatively similar results have been obtained for skeletal muscle in which skeletal CASQ also inhibited RyR2 in a Ca 2þ dependent manner. 44 
Triadin 4.2.1 Biochemistry and structure
Triadin was first identified as a 95 kDa integral membrane protein in the junctional SR vesicles isolated from skeletal muscle by Caswell et al. 45 and Knudson et al. 46 Structurally, it is composed of a short cytoplasmic N-terminal segment (47 residues); a single membrane spanning domain (20 residues), and a highly charged C-terminal region localized in the SR lumen which comprises the bulk of the protein. Subsequently, three cardiac-specific isoforms have been found (35, 40 , and 75 kDa) of which TRD-1 (40 kDa) is the most abundant form, comprising more than 95% of the total amount of TRD in cardiac myocytes. 47 Since the protein is partially glycosylated, it is present as a doublet of 35 and 40 kDa molecular weight proteins on SDS-PAGE. 47 All TRD isoforms are splice variants of the same gene. 47 They share identical sequences from residues 1-264 and the divergence after residue 264 is largely due to variations in the length of the C-terminal tail. According to in vitro binding studies, the sites for interaction of TRD with its binding partners, i.e. RyR2, CASQ2, and JCN, reside in its charged C-terminal tail. 6, 47 This portion of TRD is characterized by the frequent occurrence of long stretches of alternating positively and negatively charged residues known as KEKE motifs. These segments are considered to be protein-proteinbinding domains. The CASQ2-binding domain of TRD-1 has been localized to a single KEKE motif comprised of 15 residues (210-224). 36 Within this domain, eight even numbered, mostly charged amino acids [Lys(210)-Lys(224)] are critical for CASQ2 binding. This structure is consistent with a model that involves positively charged amino acids of TRD interacting directly with the negatively charged residues of CASQ2 to form a polar zipper that links the two proteins together. Whereas TRD binding to CASQ2 is Ca 2þ -dependent such that the proteins dissociate at high Ca 2þ (10 mM), its binding to RyR2 is independent of Ca 2þ . 36 
Triadin 1 function
Two possibilities have been considered in the literature concerning TRD function in cardiac muscle. One possibility is that TRD simply plays an anchoring role by concentrating CASQ2 near the junctional phase of the SR. In this scaffolding capacity TRD is thought to facilitate SR Ca 2þ release indirectly by permitting CASQ2 to buffer Ca 2þ in the vicinity of the release sites. 6, 36 The other possibility is that TRD directly regulates the activity of the RyR2 Ca 2þ release channel. The function of TRD has been examined in transgenic mice with cardiac overexpression of TRD. 48 Five-fold overexpression of TRD is accompanied with hypertrophy and selective downregulation of JCN and RyR2 but not CASQ2. Cardiac myocytes from TRD overexpressing mice exhibit altered Ca 2þ handling including slowed relaxation and Ca 2þ transient decay and depressed contractile strength only at low stimulation frequencies. Although demonstrating that TRD is an integral part of the Ca 2þ handling process, these results are not easily interpretable in terms of TRD's intrinsic function due to adaptive and pathological changes accompanying chronic protein overexpression. The role of TRD in cardiac EC coupling has been investigated using acute overexpression of this protein in cardiac myocytes. 49 By measuring global and local Ca 2þ transients and recordings from single RyR2 channels, it has been found that elevated TRD enhances the activity of the RyR2 Ca 2þ release channel resulting in increased spark mediated SR Ca 2þ leak, reduced SR Ca 2þ content, arrhythmogenic spontaneous releases, and membrane depolarizations, similar to those observed in myocytes expressing CPVT-linked CASQ2 mutants. These effects of TRD require a complete primary structure including the luminal tail region of the protein encompassing amino acids 200-224, as expression of a mutant protein missing this domain failed to produce any of the effects observed with its WT counterpart. Consistent with these TRD overexpression studies, re-association of purified RyR2 with TRD increases RyR2 channel open probability in lipid bilayers. 43 Interestingly, these effects of TRD and JCN could be reversed by CASQ2 in a Ca 2þ -dependent fashion. Specifically, CASQ2 inhibited the RyR2/ TRD/JCN complex at low and intermediate luminal Ca 2þ (,5 mM) but not at high Ca 2þ (.5 mM). Based on these results, it has been suggested that a dual regulation of RyR2s by TRD (or JCN) and CASQ2 accounts for the ability of RyR2s to sense and respond to changes in the SR luminal Ca 2þ . 43 
Junctin
Junctin has been identified as a 26 kDa CASQ-binding protein in cardiac and skeletal muscle junctional SR membranes. 28, 50 It is localized strictly to j SR and is absent from other SR compartments including the corbular SR. Junctin has been purified and cloned and shown to be expressed equally in skeletal and cardiac muscle. Although smaller than TRD, JCN has a similar domain structure composed of an N-terminal cytosolic segment, a membrane spanning domain, and a highly charged C-terminal tail projected into the SR. Similar to TRD, the luminal domain of JCN contains several KEKE motifs, and putative sites for protein interaction. In contrast to TRD, JCN does not appear to have a single discrete CASQ2 binding domain as deletion of any of the several KEKE motifs results in reduced CASQ2 binding. 36 In lipid bilayers, luminal JCN appears to stimulate RyR2 activity similar to TRD. 43 At the same time, acute adenoviral-mediated overexpression of JCN depresses myocyte shortening and Ca 2þ transient amplitude, 51, 52 whereas downregulation of JCN causes an increase in these parameters. 51 Although the specific mechanisms of altered cardiomyocyte contractility by manipulation of JCN are to be determined, JCN may directly regulate SR Ca 2þ cycling by affecting SR Ca 2þ load and modulating RyR2 Ca 2þ release. Cardiac-specific 5 to 10-fold overexpression of canine JCN in transgenic mice results in reduced expression of CASQ2, TRD and sodium-calcium exchanger (NCX), and hypertrophy. 53, 54 Overexpression of JCN also leads to altered myocyte Ca 2þ handling, including reduced SR Ca 2þ content, prolonged decay of Ca 2þ transients, and decreased Ca 2þ spark frequency. Notably, JCN-overexpressing myocytes exhibit marked changes in SR structure, consisting of narrowing of j SR cisternae, compaction of content i.e. CASQ2, and extension of j SR domains to non-junctional regions (i.e. 'frustrated' SR). 55, 56 Thus, JCN not only plays a role in Ca 2þ signalling but is also involved in SR morphogenesis and in assembling of the molecular components of the Ca 2þ release machinery in j SR. Recently, a genetic mouse model with cardiac specific ablation of JCN has been generated. 57 Ablation of JCN is associated with enhanced cardiac function but the JCN-deficient animals exhibit DAD-induced arrhythmias and premature mortality under conditions of physiological stress. At the myocyte level, ablation of JCN results in selective upregulation of NCX expression and function, as well as increases in SR Ca 2þ content, I Ca -induced Ca 2þ transients and sparks. Future studies will have to determine how the lack of JCN leads to enhanced Ca 2þ cycling and increased SR Ca 2þ load as well as the role of potential compensatory mechanisms in these changes. Similarly, it will be interesting to see how ablation of JCN affects SR structure.
Other sarcoplasmic reticulum proteins
There are several other intra-SR proteins that might interact with the RyR2 complex and modulate SR Ca 2þ release, including sarcalumenin, calreticulin, and a histidine-rich Ca 2þ -binding protein. 23 The specific roles of these minor SR proteins remain to be determined. Interestingly, myocytes from CASQ2 knockout mice showed a compensatory increase in the Ca 2þ -binding protein calreticulin in an apparent attempt to preserve SR Ca 2þ storing function. 58 
Abnormal ryanodine receptor luminal regulation and cardiac disease
As discussed in previous sections, RyR2 luminal Ca 2þ regulation is an important check point involved in maintaining the ordered myocyte Ca 2þ signalling required for normal cardiac function. Thus, it is not surprising that alterations in this mechanism lead to cardiac disease states. In general, defective luminal Ca 2þ signalling can arise in two ways: (i) in a variety of conditions that lead to increased SR Ca 2þ load (i.e. 'Ca 2þ overload'), sensitization of RyR2 by elevated luminal Ca 2þ contributes to generation of spontaneous Ca 2þ releases thus leading to DADs and triggered arrhythmia; (ii) acquired and genetic defects in RyR2s which enhance the responsiveness of RyR2 to luminal Ca 2þ such that the channel becomes hyperactive even at reduced SR Ca 2þ content. This state of 'perceived' Ca 2þ overload can also lead to Ca 2þ -dependent arrhythmias as shown both in certain familial tachyarrhythmias associated with mutations in RyR2 or CASQ2, and in arrhythmias during HF. Additionally, when RyR2 activity is excessively high, the SR becomes leaky resulting in depleted SR Ca 2þ stores as it may happen in HF. 
Ca 21 overload and triggered arrhythmia
Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a familial arrhythmogenic disease characterized by syncope and sudden death following exercise and emotional stress. 63 Two genetic forms of CPVT have been described: a recessive form associated with mutations in CASQ2 64, 65 and a dominant form linked to mutations in RyR2s. Since CPVT linked to RyR2 mutations have been reviewed elsewhere, 66, 67 we will focus primarily on the molecular, subcellular, and cellular mechanisms of malignant arrhythmia associated with mutations in CASQ2. Seven mutations in CASQ2 linked to CPVT have been identified so far ( Figure 3A) . 38, 64, 65, 68 How do these defects result in arrhythmia? Studies with adenoviral expression of CPVT CASQ2 mutants in cardiac myocytes ( Figure 3B and C) have suggested that various CASQ2 mutations can act through at least two different mechanisms converging on a common pathological pathway to induce irregular Ca 2þ transients and electrical activity at the myocyte level (Figure 4) ] changes acquired in a control myocyte and in a myocyte underexpressing CASQ2 and in myocytes expressing two different CPVT-linked CASQ2 mutants all stimulated at 2 Hz in the presence of 0.5 mM isoproterenol in the bathing solution.
RyR2-mediated Ca 2þ leak is a major factor in determining the reduced SR Ca 2þ content and the slowed Ca 2þ transients in HF myocytes. 78 In this model, intrinsic activities of SERCA and NCX showed no or only a relatively small change, respectively, and the reduced Ca 2þ content could be normalized by blocking the RyR2s with ruthenium red. Future studies utilizing similar techniques will have to determine whether these findings are specific to this particular model or whether they similarly apply to other models and stages of HF.
Although it is easy to understand how elevated SR Ca 2þ leak can lead to reduced SR Ca 2þ content, the existence of a sustained accelerated SR Ca 2þ leak at reduced [Ca 2þ ] SR presents a paradox (i.e.' Ca 2þ overload paradox') 72 given the established positive relationship between RyR2 activity and SR Ca 2þ content. 11, 21 Indeed, when stimulated by a RyR agonist such as caffeine, SR Ca 2þ leak increases only temporarily and then subsides due to a decline in the SR Ca 2þ content. 79 It has been proposed that local regions with elevated SR Ca 2þ content exist in HF myocytes despite the decrease in the cell-average SR Ca 2þ content 80 24 have argued that excessive phosphorylation of RyR2 by PKA (on Ser 2809) followed by dissociation of FKBP12.6 causes RyR2 to become hyperactive, i.e. leaky in HF. However, various aspects of this particular scenario have been questioned by others (e.g. Bers et al. 81 ). More recently, Bers and colleagues presented data suggesting that RyR2 phosphorylation by CAMKII (on Ser 2815) accounts for the leaky RyR2s in HF 76 (but see 82 ). Another possibility is that enhanced RyR2 activity is caused by modification of the channel protein by reactive oxygen and/or nitrogen species generated in the failing hearts. Finally, altered composition of the RyR2 channel complex due to altered expression and/or targeting of components of this complex (including CASQ2, TRD, and RyR2 itself), may also contribute to altered RyR2 function in HF. To identify the molecular causes of HF-related changes in RyR2 gating, it will be important to investigate which of the potential biochemical mechanisms, e.g. altered RyR2 phosphorylation, free radical modification, etc., is associated with altered RyR2 luminal Ca 2þ sensitivity in failing hearts. In conclusion, increased sensitivity to luminal Ca 2þ might be a common pathological alteration involved in various disease states, including HF and CPVT and may provide a therapeutic target to treat cardiac dysfunction.
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